Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/8038938> ?p ?o. }
Showing items 1 to 25 of
25
with 100 items per page.
- 8038938 classification A1.
- 8038938 date "2016".
- 8038938 language "eng".
- 8038938 type journalArticle.
- 8038938 hasPart 8039023.pdf.
- 8038938 subject "Medicine and Health Sciences".
- 8038938 doi "10.1080/17843286.2015.1108538".
- 8038938 issn "1784-3286".
- 8038938 issue "1".
- 8038938 volume "71".
- 8038938 abstract "Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by vasculopathy and progressive fibrosis of the skin and visceral organs (gastrointestinal tract, heart, kidneys and lungs). Although the prevalence is low, SSc is a disease with high morbidity and mortality. Since pulmonary arterial hypertension (PAH) associated with SSc (SSc-PAH) and clinically evident cardiac involvement is associated with increased mortality, the cardiac complications and PAH in SSc are reviewed. Both diffuse cutaneous (DcSSc) and limited cutaneous (LcSSc) subgroups are at risk for cardiac involvement and SSc-PAH. Cardiac involvement can be divided in pericardial involvement, myocardial involvement and rhythm disturbances and mostly occurs asymptomatically. However, when symptomatic, it is associated with a poor prognosis. Screening for asymptomatic cardiac involvement should be considered in SSc in order to initiate treatment in an early stage. However, there are no randomized controlled trials on treatment options for cardiac involvement in SSc. SSc-PAH is a devastating complication of SSc, which can develop early in DcSSc and LcSSc. Screening for PAH should be performed since screening leads to earlier diagnosis and earlier treatment is associated with a better prognosis. Today, screening is performed by clinical judgement and echocardiography. Recently the DETECT algorithm, a 2-step screening algorithm is proposed in a SSc-subgroup at increased risk for PAH, but further validation is needed. Despite current treatment options with prostacyclins, endothelin-1 receptor antagonists and phosphodiesterase type-5 inhibitors, mortality remains high. Several promising new treatment options for PAH are evaluated in phase II and III clinical trials.".
- 8038938 author 0751968C-B1D1-11E6-BEED-BB44B5D1D7B1.
- 8038938 author B83C2D26-DBA2-11E7-968B-A70AAE28A064.
- 8038938 author F423C6B4-F0ED-11E1-A9DE-61C894A0A6B4.
- 8038938 author F497BC5E-F0ED-11E1-A9DE-61C894A0A6B4.
- 8038938 author F83FAD26-F0ED-11E1-A9DE-61C894A0A6B4.
- 8038938 author F91A9328-F0ED-11E1-A9DE-61C894A0A6B4.
- 8038938 author FE19B6EC-F0ED-11E1-A9DE-61C894A0A6B4.
- 8038938 dateCreated "2016-07-20T11:29:56Z".
- 8038938 dateModified "2024-07-09T12:07:28Z".
- 8038938 name "The heart and pulmonary arterial hypertension in systemic sclerosis".
- 8038938 pagination urn:uuid:c012abd3-99f5-4d01-8273-60292f59d4ee.
- 8038938 sameAs LU-8038938.
- 8038938 sourceOrganization urn:uuid:191f0748-b16e-4031-bf1e-05652982399c.
- 8038938 type A1.